Genesis Therapeutics is an AI-powered drug discovery platform that utilizes advanced molecular AI technology to unlock novel protein targets, explore unexplored chemical space, and accelerate the development of new medicines.

The company's platform combines cutting-edge techniques such as 3D spatial graph modeling and molecular simulation to generate innovative drug candidates.

With a team consisting of experienced drug hunters, deep learning researchers, and software engineers, Genesis Therapeutics is focused on applying AI in biochemistry to discover and develop therapies for patients suffering from severe disorders.

By leveraging its sophisticated AI technology, Genesis Therapeutics aims to revolutionize the field of biotech and drug discovery.

The company has garnered significant attention in the press and has received substantial investments, including a recent oversubscribed $200 million Series B funding round.

Genesis Therapeutics has also formed strategic partnerships with industry giants like Eli Lilly, Roche, and Genentech, showcasing the recognition and support it has received within the biotech community.

Overall, Genesis Therapeutics is a pioneering company at the forefront of AI-driven drug discovery, utilizing advanced techniques and collaborations to accelerate the development of critical new medicines for the benefit of patients worldwide.